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LAR models outweigh any differences in lung LAR between the SIB methods.
Constraints in the planning of the SIB methods ensured that contra-lateral breast doses and LAR were comparable to WBRT, despite their added complexity. The smaller irradiated volume of the ABPI plan contributed to a halving of LAR for contralateral breast compared with the other plan types. Daily image guided radiotherapy (IGRT) for a left breast protocol using kilovoltage CBCT contributed <10% to LAR for the majority of organs, and did not exceed 22% of total organ dose.
Conclusion
Phantom measurements and calculations of LAR from the BEIR VII models predict that complex breast radiotherapy techniques do not increase the theoretical risk of second cancer incidence for organs distant from the treated breast, or the contralateral breast where appropriate plan constraints are applied. Complex SIB treatments are predicted to increase the risk of second cancer incidence in the lungs compared to standard whole breast radiotherapy ; this is outweighed by the threefold reduction in 5 year local recurrence risk for patients of high risk of recurrence, and young age, from the use of radiotherapy. APBI may have a favourable impact on risk of second cancer in the contra-lateral breast and lung for older patients at low risk of recurrence. Intensive use of IGRT increased the estimated values of LAR but these are dominated by the effect of the dose from the radiotherapy, and any increase in LAR from IGRT is much lower than the models' uncertainties.
I Introduction
The increasing use of intensity modulated radiotherapy (IMRT), and the associated increase in whole body exposure to low doses from scattered and leakage radiation, has generated interest on the possible risks of second cancer induction for patients receiving curative radiotherapy. [1] [2] [3] This issue has become of consequence because of the success of modern techniques, including radiotherapy, in increasing life expectancy for many patients with common cancers. The implications for prostate patients have been examined by a number of groups [3] [4] [5] [6] , whilst other have assessed the risks to paediatric patients, and patients under 40 years.
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Early breast cancer patients have an expectation of good long term survival and contribute a large radiotherapy treatment group. 10 There has been an increasing use of modern methods for the treatment of early breast cancer. Many authors have published IMRT techniques for whole breast treatments [11] [12] [13] [14] [15] [16] and three clinical trials using IMRT have reported dosimetric, medium and long term follow up. [17] [18] [19] [20] Baglan et al 21 described a method using non-coplanar conformal planning for accelerated partial breast irradiation (ABPI) and several groups have reported methods for simultaneous integrated boost (SIB) treatments. [22] [23] [24] [25] The increased complexity of these techniques compared to standard whole breast radiotherapy (WBRT), potentially increases the dose to non-target tissue. In addition, there is often a need to use Image Guided Radiotherapy (IGRT), for example, in partial breast irradiation (PBI), or to achieve specific planning target volume (PTV) margins 25 .
There has been discussion over the increased use of imaging, and hence dose from IGRT systems. [26] [27] [28] [29] [30] . Gy to whole breast and 74 Gy to the tumour bed in 31 fractions. Two IMRT fields were used to treat the whole breast and three conformal fields used to treat the tumour bed PTV. Beam weight optimisation was applied to these latter beams. The most complex treatment was a three volume SIB IMRT plan designed to deliver 36Gy to whole breast, 40Gy to partial breast and 53Gy to the tumour bed in 15 fractions.
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The plan consisted of tangential fields to cover the whole breast, plus 5 co-planar fields to deliver the dose to the partial breast and the tumour bed PTV. Beam weights, segment weights and MLC shaping were designed using both forward or inverse planning approaches as described by Donovan et al. 35 Sagittal dose distributions are shown in Figure 1 . The 2Gy equivalent dose (EQD 2 ) for each fractionation regimen is given in Table 1 assuming an β α / ratio of 3 for tumour control 36 .
II.B Measurement of Treatment Doses in an Anthropomorphic Phantom
The plans were transferred to a CT scan of a Rando anthropomorphic phantom which had semi-realistic breast attachments added. An experienced clinician (MB) . The uncertainties associated with each of the models are close to, or exceed, the variation between the models 32 . We have chosen to use the BEIR VII model as it provides model parameters for specific organs for each sex and includes a parameter describing incidence with age at exposure and attained age. Our focus was to estimate cancer incidence over an age range of 35 to 80 years (which reflects the typical age distribution of breast cancer incidence in Europe and the US).
II.C Measurement of Cone Beam CT Doses in an Anthropomorphic Phantom
We have evaluated Lifetime Attributable Risk (LAR) via the method given in the BEIR VII report, with a slight modification to sum to age 90. This summation gave consistency with the data from ICRP Report 103 33 , which is required in the calculation of LAR, but is not stratified above age 90 years. Equation 2 is the BEIR committee recommended model for both Excess Relative Risk (ERR) and Excess Absolute Risk (EAR).
ERR and EAR
where D = dose; β S , γ and η are ERR and EAR specific parameters for various organs for each sex; e is age at exposure; e*= (e-30)/10 for e<30 and 0 for e>30 years; a is attained age.
For organs other than breast, lung and thyroid the BEIR VII report recommends calculating Lifetime Attributable Risk (LAR) as given in equation 3.
ERR (D,e,a,) and EAR (D,e,a) Linear scaling has been used to calculate LAR for the mean organ doses presented in this work. A dose and dose-rate effective factor (DDREF) of 1.5, as recommended in the BEIR VII report, was applied to the calculated LAR. Table 1 shows the mean dose per organ from the radiotherapy deliveries and the total for 15 CBCT imaging exposures. The data are stratified into three dose levels <0.5Gy; ≥ 0.5 and < 1.0Gy; ≥ 1.0Gy. These data are expressed as a percentage of maximum prescribed dose in Table 2 . Table 3 expresses the CBCT organ doses as a percentage of total (radiotherapy plus imaging) doses assuming online verification of each treatment fraction for each schedule. The mean background output of the TLD was 0.1nC± 0.03nC; the lowest TLD output from an irradiation session was 1.2nC.
III Results

III.A Measured Organ Doses
The uncertainties in the measured dose from individual TLDs ranged from 2.5% to 6.5%, with a median of 3.4% at 6MV; 2.4% to 6.1% with a median of 2.8% at 100kVp. These quoted uncertainties were based on a standard uncertainty multiplied by a coverage factor k = 2, providing a level of confidence of approximately 95%.
The pattern in the dose data was as expected. Distant organs (brain, salivary glands, thyroid, colon, bladder) received mean doses less than 0.2Gy with higher doses close to the treated region. Organs received the lowest doses from the APBI techniques because of the smaller volume irradiated and lower prescribed dose. The three complex SIB techniques delivered higher doses to more organs than the standard whole breast method. The main difference between the SIB techniques was in the mean contra-lateral lung and oesophagus doses. Whilst doses from the CBCT imaging were low compared to these from the radiotherapy, they contributed 10% to 20% of total organ dose in some cases (Table 3) .
III.B Lifetime Attributable Risk
The uncertainties in estimated LAR based on the models presented in the BEIR VII per 100,000 of mixed age exposed to 0.1Gy. For lung cancer incidence in females of the same population and dose, LAR is given as 300 (95% CI 120, 780). Other sites have similar levels of uncertainty.
LAR data for all radiotherapy techniques from age at exposure of 35 to 90 years for each measured organ are given in Tables 4 and 5 and assumed to have uncertainty levels as discussed. The data were separated by class of plan. Whole breast and ABPI were considered as applicable to patients with low recurrence risk (Table 4) ; the SIB methods appropriate for cohorts with high recurrence risk ( Table 5 ). The LAR data show the strong age dependency of the cancer incidence risk in the BEIR VII model. This is pronounced in the breast data where there is a 60 fold decrease in . EBCTCG data show an increase in lung and contra-lateral breast second cancers following radiotherapy; LAR for these at risk organs is plotted in Figure 3 . The data and techniques are separated as for Tables 4 and 5 . For the specific plans and equipment used in this work, LAR are predicted to be low for all techniques compared to the gain from radiotherapy which reduces 5 year recurrence from 33%
to 11% for a cohort of 40 year old women, and from 11% to 4% for a population of 60 year old women.
IV Discussion
We have described measured out-of-field doses, and presented estimated LAR for cancer incidence, for standard whole breast and four complex breast treatments over a range of organs delineated in an anthropomorphic phantom. The data have been used to assess the change in risk of second cancer incidence for complex deliveries compared to standard whole breast radiotherapy.
The analysis of the EBCTCG 10 shows both lung and contra-lateral breast second cancer incidence increased with the use of radiotherapy. There is much interest in hypofractionated and accelerated schedules for early breast cancer. These result in lower total physical doses, for example, the UK Faster Radiotherapy for Breast Cancer patients (FAST) trial of 30Gy in 5 fractions 49 and the US APBI study of 38.5Gy in 10 fractions. 333 The BEIR VII models do not include a 
V Conclusions
The dose measurements and calculations of LAR presented indicate that more sophisticated methods for breast radiotherapy do not increase the theoretical risk of second cancer incidence for organs distant from the treated breast. Complex SIB treatments are predicted to increase the risk of second cancer in the lungs compared to standard whole breast radiotherapy, however, this is outweighed by the threefold reduction in 5 year local recurrence risk for patients of high risk of recurrence and young age. If dose constraints for the contra-lateral breast are set so that they do not exceed those of standard tangents, then complex methods do not increase LAR, although age specific contra-lateral breast dose constraints could be considered in clinical trials of breast radiotherapy. APBI may have a favourable impact on risk of second cancer in the contra-lateral breast for older patients at low risk of recurrence.
Intensive use of IGRT theoretically increases the estimated values of LAR but these are dominated by the effect of the dose from the radiotherapy, and any increase in LAR from IGRT is much lower than the uncertainty in the models. Whilst appropriate imaging protocols should be used, daily imaging using CBCT of patients at high risk of recurrence receiving complex radiotherapy is unlikely on its own to result in an unacceptable increase in the risk of second cancer. 
